Top 6 Research Reports For June 29, 2016

Amgen (AMGN) to Gain from Cost Savings, Blockbuster Drugs

Strong Margins Offset Weak Sales for Kraft Heinz (KHC)

Strong Fundamentals & Investments Drive Growth at UPS

Gilead's (GILD) Drug Gains FDA Approval

Gilead has received a boost with the FDA approving the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.

AbbVie (ABBV) Terminates Infinity Collaboration for Duvelisib

AbbVie terminated its partnership with Infinity for the development and commercialization of duvelisib (cancer) and returned global rights to the candidate.

Whirlpool (NYSE:WHR) Keeps Guidance Intact Despite Brexit

The Zacks analyst stresses that Whirlpool has reassured investors following Brexit by reiterating its earnings guidance for 2016.

ETE Announces Merger Termination with Williams (WMB)

Termination of the merger will impact shareholders since they will miss a cash payment and lose the chance to own a stake in a stronger combined entity, according to the covering analyst.

Ball Corporation (NYSE:BLL) Gets FTC's Final Nod for Rexam Buy

The deal, on closing, will create the world's largest manufacturer of food and beverage cans.

Brexit to Have Limited Impact on Expedia (EXPE)

While Brexit has increased volatility in Expedia shares, the Zacks analyst thinks its strong order growth and contribution from acquisitions will be the major growth drivers.

HSBC's (HSBC) Profitability under Pressure Post Brexit

The covering analyst feels revenue growth will remain muted given rising macro concerns after the Brexit vote while Moody's ratings outlook revisions will have an adverse impact on its financials.

Shire (SHPG) Poised to Gain from Diversified Portfolio

The Zacks analyst believes Shire has been making timely aquisitions to diversify its portfolio and the recent Baxalta acquisition strengthens its hematology, oncology and immunology franchises.n

Archer Daniels' (ADM) Growth Efforts on Track

Archer Daniels is strategically undertaking steps to manage its business portfolio, which is expected to help in realizing value, according to the covering analyst. n

Automatic Data (ADP) Shines on Strong Fundamentals

The Zacks analyst stresses that ADP's higher revenue per client and lower cost of operations gives it an edge amid volatile macro-economic backdrop and a strengthening U.S dollar.

Brexit Risks May Weigh on United Technologies (NYSE:UTX)

The Zacks analyst thinks United Technologies is susceptible to operating risks following the referendum given its considerable presence in the Britain.

Dr Pepper (DPS) to Face Headwinds in Q2

The covering analyst believes currency headwinds, possible softer fountain food-service volumes, higher health and welfare insurance costs will hurt profits in the second quarter.n

Barclays (BCS) Outlook Cut by Moody's Post-Brexit

Barclays' outlook was cut to negative by Moody's in the wake of Brexit concerns while fundamental weakness persist, according to the covering analyst.